Log in

NASDAQ:SCYX - SCYNEXIS Stock Price, Forecast & News

$0.98
+0.04 (+4.26 %)
(As of 02/17/2020 02:17 AM ET)
Add
Today's Range
$0.93
Now: $0.98
$1.00
50-Day Range
$0.84
MA: $0.94
$1.10
52-Week Range
$0.70
Now: $0.98
$1.90
Volume699,236 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
SCYNEXIS, Inc is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:SCYX
CUSIPN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees24
Next Earnings Date3/12/2020 (Estimated)
OptionableOptionable

Receive SCYX News and Ratings via Email

Sign-up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter.


SCYNEXIS (NASDAQ:SCYX) Frequently Asked Questions

What is SCYNEXIS's stock symbol?

SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX."

How were SCYNEXIS's earnings last quarter?

SCYNEXIS Inc (NASDAQ:SCYX) announced its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.18) by $0.02. The company had revenue of $0.06 million for the quarter, compared to analysts' expectations of $0.06 million. View SCYNEXIS's Earnings History.

When is SCYNEXIS's next earnings date?

SCYNEXIS is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for SCYNEXIS.

What price target have analysts set for SCYX?

6 brokerages have issued 1-year price targets for SCYNEXIS's shares. Their forecasts range from $3.50 to $6.00. On average, they expect SCYNEXIS's stock price to reach $4.63 in the next twelve months. This suggests a possible upside of 371.9% from the stock's current price. View Analyst Price Targets for SCYNEXIS.

What is the consensus analysts' recommendation for SCYNEXIS?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SCYNEXIS.

What are Wall Street analysts saying about SCYNEXIS stock?

Here are some recent quotes from research analysts about SCYNEXIS stock:
  • 1. According to Zacks Investment Research, "SCYNEXIS, Inc. is a pharmaceutical company. It is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. It also provides contract research and development services. SCYNEXIS, Inc. is headquartered in Durham, North Carolina. " (1/14/2020)
  • 2. Needham & Company LLC analysts commented, "Scynexis reported 1Q19 financial results this wk and we spoke w/ mgmt for an update. Enrollment in ibrexafungerp Phase 3 VANISH program in Acute Vulvovaginal Candidiasis (VVC) is progressing and mgmt reiterated guidance for top-line results in 1H20. Phase 3 CANDLE trial in Recurrent VVC is expected to start in 2Q19 (unch). Reiterate BUY. We believe commercial opportunity in VVC is substantially underappreciated by investors given there are no oral options for pts w/ poor response to standard of care oral fluconazole. Recent encouraging data from FURI and CARES trials demonstrating impressive activity against challenging infections (including tied to C. auris) enhances overall profile." (5/12/2019)
  • 3. Maxim Group analysts commented, "Scynexis reported FY18 with operating expenses of $30.2M and a net loss of ($12.5M). The company ended the period with $44.2M in cash, excluding the sale of a portion of its business, and tax net operating losses (NOLs) in $6.7M, netting a pro forma cash balance of $51M in January. Scynexis also completed the sale of a $16.0M convertible note to March, which the company used to retire in full a previous term loan, strengthening its balance sheet further. Combined, Scynexis has runway at the current burn rate through key catalysts, including the NDA submission of ibrexafungerp for acute vulvovaginal candidiasis (VVC) in 2H20." (3/18/2019)

Has SCYNEXIS been receiving favorable news coverage?

News headlines about SCYX stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. SCYNEXIS earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for SCYNEXIS.

What other stocks do shareholders of SCYNEXIS own?

Who are SCYNEXIS's key executives?

SCYNEXIS's management team includes the folowing people:
  • Marco Taglietti, President, Chief Executive Officer & Director
  • Eric Francois, Chief Financial Officer
  • David Angulo Gonzalez, Chief Medical Officer
  • Rajeshwar Motheram, Vice President-Pharmaceutical Development
  • Scott Sukenick, General Counsel

Who are SCYNEXIS's major shareholders?

SCYNEXIS's stock is owned by a number of of institutional and retail investors. Top institutional investors include Broadfin Capital LLC (3.43%), Renaissance Technologies LLC (1.18%), Creative Planning (0.29%), Puissance Capital Management LP (0.22%), Jane Street Group LLC (0.09%) and Connor Clark & Lunn Investment Management Ltd. (0.09%). Company insiders that own SCYNEXIS stock include David C Hastings, Eric Francois, Gonzalez David Angulo, Marco Taglietti and Scott Sukenick. View Institutional Ownership Trends for SCYNEXIS.

Which major investors are selling SCYNEXIS stock?

SCYX stock was sold by a variety of institutional investors in the last quarter, including Puissance Capital Management LP. View Insider Buying and Selling for SCYNEXIS.

Which major investors are buying SCYNEXIS stock?

SCYX stock was purchased by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Renaissance Technologies LLC, Connor Clark & Lunn Investment Management Ltd., Jane Street Group LLC and Creative Planning. Company insiders that have bought SCYNEXIS stock in the last two years include David C Hastings, Eric Francois, Gonzalez David Angulo, Marco Taglietti and Scott Sukenick. View Insider Buying and Selling for SCYNEXIS.

How do I buy shares of SCYNEXIS?

Shares of SCYX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is SCYNEXIS's stock price today?

One share of SCYX stock can currently be purchased for approximately $0.98.


MarketBeat Community Rating for SCYNEXIS (NASDAQ SCYX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  442 (Vote Outperform)
Underperform Votes:  346 (Vote Underperform)
Total Votes:  788
MarketBeat's community ratings are surveys of what our community members think about SCYNEXIS and other stocks. Vote "Outperform" if you believe SCYX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SCYX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel